UA72286C2 - Alkaline salts n-(6-alkyl-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinsulfone)-n'-izonicotinoylhydrazide which can be used as antimicrobial and immunotropic agents, a method for the preparation thereof, use thereof as immunomodulator and pharmaceutical composition based thereon - Google Patents
Alkaline salts n-(6-alkyl-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinsulfone)-n'-izonicotinoylhydrazide which can be used as antimicrobial and immunotropic agents, a method for the preparation thereof, use thereof as immunomodulator and pharmaceutical composition based thereon Download PDFInfo
- Publication number
- UA72286C2 UA72286C2 UA2002064588A UA2002064588A UA72286C2 UA 72286 C2 UA72286 C2 UA 72286C2 UA 2002064588 A UA2002064588 A UA 2002064588A UA 2002064588 A UA2002064588 A UA 2002064588A UA 72286 C2 UA72286 C2 UA 72286C2
- Authority
- UA
- Ukraine
- Prior art keywords
- alkyl
- dioxo
- tetrahydro
- antimicrobial
- alkaline salts
- Prior art date
Links
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 15
- 159000000011 group IA salts Chemical class 0.000 title claims abstract description 11
- 239000002955 immunomodulating agent Substances 0.000 title claims abstract description 8
- 230000002584 immunomodulator Effects 0.000 title claims abstract description 8
- 229940121354 immunomodulator Drugs 0.000 title claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 title claims description 13
- 230000000686 immunotropic effect Effects 0.000 title claims description 7
- 239000003795 chemical substances by application Substances 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title description 3
- 206010061598 Immunodeficiency Diseases 0.000 claims abstract description 5
- 208000029462 Immunodeficiency disease Diseases 0.000 claims abstract description 5
- 230000007813 immunodeficiency Effects 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 4
- 230000001684 chronic effect Effects 0.000 claims abstract description 4
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 3
- 150000001340 alkali metals Chemical group 0.000 claims abstract description 3
- 239000013543 active substance Substances 0.000 claims description 10
- 230000000306 recurrent effect Effects 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 26
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 24
- 229940079593 drug Drugs 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 15
- DVAIYSZTXVOUQZ-UHFFFAOYSA-N diucifon Chemical compound N1C(=O)NC(=O)C(S(=O)(=O)NC=2C=CC(=CC=2)S(=O)(=O)C=2C=CC(NS(=O)(=O)C=3C(NC(=O)NC=3C)=O)=CC=2)=C1C DVAIYSZTXVOUQZ-UHFFFAOYSA-N 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 230000002558 anti-leprotic effect Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000002365 anti-tubercular Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000009631 Broth culture Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 241000208202 Linaceae Species 0.000 description 2
- 235000004431 Linum usitatissimum Nutrition 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000000403 immunocorrecting effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000000891 standard diet Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940053973 novocaine Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU99123407/14A RU2191015C2 (ru) | 1999-11-05 | 1999-11-05 | Динатриевая соль n-(6-метил-2,4-диоксо-1,2,3,4-тетрагидро-5h-пиримидинсульфон)-n'- изоникотиноилгидразида, проявляющая антимикробную и иммунотропную активность, и лекарственное средство на ее основе |
| PCT/RU2000/000438 WO2001032650A2 (fr) | 1999-11-05 | 2000-11-03 | Sels alcalins de n-(6-alkyle-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinesulfone)-n'-isonicotinoylhydrazide pouvant presenter une activite antimicrobienne et immunotrope, methode de preparation de ces sels, utilisation de ces sels comme immunomodulateurs et composition pharmaceutique a base de ces sels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA72286C2 true UA72286C2 (en) | 2005-02-15 |
Family
ID=20226671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002064588A UA72286C2 (en) | 1999-11-05 | 2000-03-11 | Alkaline salts n-(6-alkyl-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinsulfone)-n'-izonicotinoylhydrazide which can be used as antimicrobial and immunotropic agents, a method for the preparation thereof, use thereof as immunomodulator and pharmaceutical composition based thereon |
Country Status (5)
| Country | Link |
|---|---|
| AU (1) | AU1423701A (fr) |
| EA (1) | EA200200540A1 (fr) |
| RU (1) | RU2191015C2 (fr) |
| UA (1) | UA72286C2 (fr) |
| WO (1) | WO2001032650A2 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA013052B1 (ru) * | 2004-03-26 | 2010-02-26 | Закрытое Акционерное Общество "Новая Линия" | Лекарственное средство |
| ME01644B (me) * | 2004-06-23 | 2014-09-20 | Synta Pharmaceuticals Corp | BIS(TIO-HIDRAZID AMIDNE) SOLl ZA TRETMAN KANCERA |
| RU2368609C1 (ru) * | 2008-01-09 | 2009-09-27 | Лев Давидович Раснецов | Серебряная соль n-(6-метил-2,4-диоксо-1,2,3,4-тетрагидро-5h-пиримидинсульфон)-n'-изоникотиноилгидразида, проявляющая иммунотропную, противомикробную, противогрибковую (противомикотическую) активность, и лекарственное средство на ее основе |
| MD4075C1 (ro) * | 2009-12-31 | 2011-07-31 | Анатолий ЭФКАРПИДИС | Procedeu de obţinere a argintului coloidal de înaltă dispersie |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1620445A1 (de) * | 1965-04-15 | 1970-04-16 | Schering Ag | Verfahren zur Herstellung von substituierten Hydrazonen |
| GB1206567A (en) * | 1969-03-27 | 1970-09-23 | Fargal Pharmasint Lab Biochim | Substituted benzal hydrazone, organic and inorganic salts thereof and processes of preparation therefor |
| RU2141322C1 (ru) * | 1997-08-12 | 1999-11-20 | Голощапов Николай Михайлович | Иммуномодулятор с антимикобактериальной активностью "изофон", способ его получения и применения |
| RU2136668C1 (ru) * | 1997-10-07 | 1999-09-10 | Голощапов Николай Михайлович | N,n'-(сульфонилди-1,4-фенилен)бис(n'',n''- диметилформамидин)1,2,3,4-тетрагидро-6-метил-2,4- диоксо-5-пиримидинсульфонат, стимулирующий клеточный метаболизм и обладающий иммунотропной и антимикобактериальной активностью |
-
1999
- 1999-11-05 RU RU99123407/14A patent/RU2191015C2/ru not_active IP Right Cessation
-
2000
- 2000-03-11 UA UA2002064588A patent/UA72286C2/uk unknown
- 2000-11-03 WO PCT/RU2000/000438 patent/WO2001032650A2/fr active Application Filing
- 2000-11-03 EA EA200200540A patent/EA200200540A1/ru unknown
- 2000-11-03 AU AU14237/01A patent/AU1423701A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA200200540A1 (ru) | 2002-10-31 |
| AU1423701A (en) | 2001-05-14 |
| RU2191015C2 (ru) | 2002-10-20 |
| WO2001032650A2 (fr) | 2001-05-10 |
| WO2001032650A3 (fr) | 2002-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2673136B2 (ja) | 抗腫瘍性、抗ウイルス性、抗レトロウイルス性、抗乾癬性および殺虫性スペルミン誘導体 | |
| CN105189607A (zh) | 胺官能性聚酰胺 | |
| SK138597A3 (en) | A pharmaceutical composition containing n-chlorophenylcarbamates, n-chlorophenylthiocarbamates and n-phosphonoglycine derivatives for inhibiting the growth of cancers and viruses in mammals | |
| JPH031309B2 (fr) | ||
| CN101370783A (zh) | 9-氧代吖啶-10-乙酸和1-烷基氨基-1-脱氧多羟基化合物的盐和混合物、包含其的药物组合物以及治疗方法 | |
| UA72286C2 (en) | Alkaline salts n-(6-alkyl-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinsulfone)-n'-izonicotinoylhydrazide which can be used as antimicrobial and immunotropic agents, a method for the preparation thereof, use thereof as immunomodulator and pharmaceutical composition based thereon | |
| JPS61171495A (ja) | 白金錯体類及びその製造方法 | |
| RU2056416C1 (ru) | Производные тиомочевины, фармацевтическая композиция и способ лечения | |
| EA001412B1 (ru) | Иммуномодулятор с антимикробной и антимикобактериальной активностью, способ его получения и лекарственный препарат для лечения микобактериозов, хронических неспецифических заболеваний легких, заболеваний, передающихся половым путем, и иммунодефицита на их основе | |
| CN110981888B (zh) | N-芳基二硫吡咯酮脲类和氨基酯类衍生物及其制备和应用 | |
| WO2013130738A1 (fr) | Composés et procédés permettant de traiter le paludisme | |
| RU2264396C2 (ru) | 6-алкил-5-(2-изоникотиноилсульфогидразоил)урацилгидрохлорид и фармацевтическая композиция на его основе | |
| RU2136668C1 (ru) | N,n'-(сульфонилди-1,4-фенилен)бис(n'',n''- диметилформамидин)1,2,3,4-тетрагидро-6-метил-2,4- диоксо-5-пиримидинсульфонат, стимулирующий клеточный метаболизм и обладающий иммунотропной и антимикобактериальной активностью | |
| CN107007608B (zh) | I型和ii型糖尿病的治疗 | |
| US7704976B2 (en) | Use of N-acetyl-D-glucosamine for preparing medicines for urogenital tract infection's treatment and prevention | |
| JPH10507446A (ja) | ビス−２−アミノピリジン類、その製造方法及び寄生虫感染を制御するためのその用途 | |
| CS210659B2 (en) | Method of preparation of amidobenzoic acid derivatives | |
| WO2012158002A1 (fr) | Préparation médicinale « renessans » à action antibactérienne, anti-ulcère et immunomodulatrice | |
| AU679676B2 (en) | Ion pairs of hypericin compounds having antiviral activity | |
| US2702777A (en) | Veterinary tetravalent tin compositions | |
| RU2197248C2 (ru) | Лекарственный препарат, обладающий иммуномоделирующим, иммунокоррегирующим, противопаразитарным, противосклеротическим, противовирусным, противобактериальным, противогрибковым, противовоспалительным и противоопухолевым действием, и способ его приготовления | |
| JPS59222417A (ja) | Ｎ，Ｎ−ジエチル−５−メチル−２Ｈ−１−ベンゾチオピラノ−〔４，３，２−ｃｄ〕−インダゾ−ル−２−エタナミン組成物 | |
| US11958817B1 (en) | 4-chloro-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound | |
| US11970476B1 (en) | 6′-(4-chlorophenyl)-2′-alkoxy-3,4′-bipyridine-3′-carbonitriles as antimicrobial compounds | |
| RU2032660C1 (ru) | Способ получения комплексов на основе ациклических аминов, обладающих радиопротекторными свойствами |